文献速递乳腺癌放疗泌尿生殖与妇科肿瘤放疗放疗物理与技术

按保险类型和治疗方式估算放射治疗的患者自付费用

Estimation of Patient Out-of-Pocket Cost for Radiation Therapy by Insurance Type and Treatment Modality.
PubMed 文献 · Pract Radiat Oncol · 2022-04-18

回顾性分析247例接受根治性放疗的非转移性乳腺癌和前列腺癌患者,其中乳腺137例、前列腺110例。商业保险和 Medicare Advantage 计划的年均自付上限分别为4064美元和4661美元,100%商业保险患者和54.7%的 Medicare Advantage 患者在接受放疗期间达到自付上限。多因素分析显示同步全身治疗与达到自付上限相关(OR 6.20,P=0.03),而放疗技术与之无关。

要点

  • 商业保险患者100%在放疗期间达到年度自付上限,Medicare Advantage 患者为54.7%。
  • Medicare 补充保险、Medicaid 和 Tricare 的年度自付上限极低。
  • 同步全身治疗与达到自付上限相关(OR 6.20,P=0.03),放疗技术与之无关。

核心结论

  • 放疗自付费用可根据保险类型和结构合理估算;商业保险患者均达到年度自付上限,而 Medicare 补充保险和 Medicaid 的自付费用可忽略不计。

研究设计与样本

  • 回顾性分析247例连续接受根治性放疗的非转移性乳腺癌和前列腺癌患者,收集人口学、治疗和保险计划参数,采用多因素逻辑回归分析达到自付上限的相关因素。

主要发现

  • 商业保险和 Medicare Advantage 计划的年均自付上限分别为4064美元和4661美元。
  • 100%的商业保险患者和54.7%的 Medicare Advantage 患者在接受放疗期间达到自付上限。
  • Medicare 补充保险、Medicaid 和 Tricare 的年度自付上限极低。
  • 多因素分析中,同步全身治疗与达到自付上限相关(OR 6.20,P=0.03),放疗技术与之无关。

临床怎么用

  • 本研究为提供者更好地向患者咨询提供了实用信息。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Financial toxicity is increasingly identified as an important issue in cancer care. Limited data are available on direct out of pocket (OOP) costs for radiation therapy, which are important for providers and patients. METHODS AND MATERIALS: Retrospective analysis of 247 consecutive patients with nonmetastatic breast and prostate cancer treated with curative intent. Data were collected on demographics, treatments received and insurance plan specifications, including annual OOP maximum, deductibles, co-insurance rates, OOP already paid prior to starting radiation therapy, and actual estimated OOP for radiation therapy. Multivariable logistic regression was used to examine associations between insurance factors, radiation technique, concurrent systemic therapy, and month of treatment with a patient reaching OOP maximum with radiation treatment. RESULTS: In the study, 137 and 110 patients with breast and prostate cancer were evaluated. Mean plan specified annual OOP maximum for commercial and Medicare Advantage plans were $4064 and $4661, respectively; 100% of commercially insured patients and 54.7% Medicare Advantage patients reached their OOP maximum with radiation therapy. Annual OOP maximum for Medicare plus supplement, Medicaid, and Tricare were minimal. On multivariable analysis, concurrent systemic therapy (odds ratio 6.20, P = .03) was associated with patient reaching OOP maximum, but radiation technique was not. CONCLUSIONS: Out of pocket cost for radiation therapy services may be reasonably estimated based on insurance type and structure. Medicare plus supplement and Medicaid plans have negligible OOP, while all patients with commercial plans reached annual OOP maximums. This study provides practical information to help providers to better counsel patients.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen LW, Cao Y, D'Rummo K, et al. Estimation of Patient Out-of-Pocket Cost for Radiation Therapy by Insurance Type and Treatment Modality. Pract Radiat Oncol. 2022. PMID: 35447387. doi:10.1016/j.prro.2022.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。